Clinical trial
Safety Study of Combination Chemotherapy in Patients With Metastatic Solid…
NCT00220649 · St. Luke's-Roosevelt Hospital Center, Other · Completed
Key facts
| NCT number | NCT00220649 |
|---|---|
| Title | Safety Study of Combination Chemotherapy in Patients With Metastatic Solid Tumors or Adenocarcinoma of the Pancreas |
| Official title | Phase I Study to Determine the Safety, Maximum Tolerated Dose, and Efficacy of Biweekly Oxaliplatin (Eloxatin) in Combination With Gemcitabine, Irinotecan, and 5-FU/Leucovorin (G-Flie) in Patients With Metastatic Solid Tumors or Adenocarcinoma of the Exocrine Pancreas |
| Lead sponsor | St. Luke's-Roosevelt Hospital Center, Other |
| Collaborators | Sanofi Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Pancreatic Neoplasms |
| Intervention type | Drug |
| Interventions | gemcitabine, irinotecan, leucovorin, 5-fluorouracil, oxaliplatin |
| Enrollment | 25 |
| Start date | Mar 1, 2004 |
| First posted | Sep 22, 2005 |
| Last update posted | Aug 17, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: